Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure Aug 11 Written by Holly Plante Watch here Holly Plante Previous Previous Public Service Announcement: Phase 2 clinical trial for Oxeia’s concussion drug, OXE103 Next Next One Nucleus: Dr. Michael Wyand to participate in panel
Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure Aug 11 Written by Holly Plante Watch here Holly Plante
